Search
Brain Metastases Clinical Trials
A listing of 43 Brain Metastases clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 43
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Brain Metastases
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 43 active clinical trials seeking participants for Brain Metastases research studies. The states with the highest number of trials for Brain Metastases participants are Michigan, California, New York and North Carolina.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
REMASTer: REcurrent Brain Metastases After SRS Trial
Recruiting
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: UCLA, Los Angeles, California +8 locations
Conditions: Brain Metastases, Radiation Necrosis, Recurrent Tumor, Recurrent Metastases
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
Recruiting
The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has spread to the brain. The researches will also look at how the study treatment affects the quality of life of participants. They will measure the quality of life by having participants complete questionnaires.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Metastatic Renal Cell Carcinoma, Brain Metastases
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Recruiting
The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Hartford Healthcare (Data Collection Only), Hartford, Connecticut +7 locations
Conditions: Lung Cancer, Lung Cancer Metastatic, Brain Metastases, Brain Metastases, Adult, Small-cell Lung Cancer, Small Cell Lung Carcinoma
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
Recruiting
To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Solid Tumor, Brain Metastases
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
Recruiting
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: HonorHeath Scottsdale Osborn Medical Center, Phoenix, Arizona +37 locations
Conditions: Brain Metastases
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
Recruiting
This is a trial that evaluates the preservation of cognition and neuropsychiatric function following genu-sparing whole brain radiation in patients with brain metastases.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/30/2025
Locations: Sibley Memorial Hospital, Washington, District of Columbia +1 locations
Conditions: Brain Metastases
Study Assessing QBS72S For Treating Brain Metastases
Recruiting
This study is to evaluate the efficacy and safety of QBS72S in participants with advanced, relapsed, metastatic cancer with CNS involvement
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Stanford Cancer Institute, Palo Alto, California
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
Recruiting
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain.
Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hipp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona +85 locations
Conditions: Brain Metastases
Development of MRF for Characterization of Brain Tumors After Radiotherapy
Recruiting
The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This is an advanced quantitative assessment of brain tissues. This method is being applied with IVIM MRI to be able to tell the difference between a brain with radiation necrosis and a brain with tumor recurrence. Participan... Read More
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
06/05/2025
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio +1 locations
Conditions: Brain Tumor, Brain Necrosis, Brain Metastases, Glioma
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
Recruiting
To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Brain Metastases
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers
Recruiting
BDTX-4933-101 is a first-in-human, open-label, Phase 1 dose escalation and an expansion cohort study designed to evaluate the safety and tolerability, maximum tolerated dose (MTD) and the preliminary recommended Phase 2 dose (RP2D), and antitumor activity of BDTX-4933. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC) harboring KRAS non-G12C mutations, BRAF, or CRAF (RAF1) mutations, advanced/meta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Banner Health- MD Anderson Cancer Center, Gilbert, Arizona +9 locations
Conditions: Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, Melanoma, Melanoma (Skin), BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Lung Cancer, Recurrent Melanoma, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Phase I Study of Fractionated Stereotactic Radiation Therapy
Recruiting
There is a lack of prospective trial data and consensus guidelines describing the use of Fractionated Stereotactic Radiation Therapy (FSRT) in the treatment of brain metastases. There has been no prospective dose escalation study performed to date to determine the maximum tolerated dose (MTD) in patients treated with FSRT. Prescription doses in the series described above ranged from 18 Gy to 42 Gy, delivered in 3 to 12 fractions. The results of this study will be used to plan future Phase II/III... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Brain Metastases
1 - 12 of 43